Importantly, a retrospective analysis of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) showed that treatment with anti-IL-1β antibody, canakinumab, drastically reduced incidence and mortality of lung cancer in patients with prior myocardial infraction [23]. Here, IL1B is linked to lung cancer.